Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells

被引:0
|
作者
Lapidus, RG
Tiffany, CW
Isaacs, JT
Slusher, BS
机构
[1] Guilford Pharmaceut Inc, Baltimore, MD 21224 USA
[2] Johns Hopkins Oncol Ctr, Baltimore, MD USA
来源
PROSTATE | 2000年 / 45卷 / 04期
关键词
glutamate carboxypeptidase; glutamate; NAALADase; NAAG diagnostic; BPH; prostate cancer;
D O I
10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate-specific membrane antigen (PSMA) is a glutamate carboxypeptidase that cleaves terminal carboxy glutamates from both the neuronal dipeptide N-acetylaspartylglutamate (NAAG) and gamma-linked folate polyglutamate. The prostate enzyme has activity in both the membrane and cytosolic fractions termed PSMA and PSMA', respectively. METHODS. Using a NAAG hydrolytic radioenzymatic assay, we quantitated the enzymatic activity of PSMA and PSMA' in normal, benign prostatic hyperplasia (BPH), and prostate cancer (PC) tissues from radical prostatectomies. PSMA enzyme activity was evaluated in each tissue type and expressed per milligram protein and epithelial cell content. RESULTS. PSMA and PSMA' enzyme activities were significantly elevated in prostate cancer when compared to normal prostate tissue and BPH. Ratios of PSMA to PSMA' were also decreased in BPH as compared to cancerous and normal tissue. CONCLUSIONS. Prostate carcinogenesis is associated with an elevation in PSMA and PSMA' enzyme activity. In contrast, no such enhancement in PSMA activity is observed with benign neoplastic changes in BPH. Thus, the enhancement observed in prostate cancer is not simply related to a generalized prostatic hyperplasia, but is specific to its malignancy. (C) 2000 Wiley-Liss, Inc.
引用
收藏
页码:350 / 354
页数:5
相关论文
共 50 条
  • [41] Studies on the effect of androgens on the promoter activity of the prostate specific membrane antigen (PSMA) gene in prostate cancer cells
    Noss, K
    Grimes, SR
    MOLECULAR BIOLOGY OF THE CELL, 2000, 11 : 435A - 435A
  • [42] Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
    Gong, MC
    Chang, SS
    Sadelain, M
    Bander, NH
    Heston, WDW
    CANCER AND METASTASIS REVIEWS, 1999, 18 (04) : 483 - 490
  • [43] Prostate-specific membrane antigen as a marker of pancreatic cancer cells
    Ren, He
    Zhang, Huan
    Wang, Xiuchao
    Liu, Junxiu
    Yuan, Zhanna
    Hao, Jihui
    MEDICAL ONCOLOGY, 2014, 31 (03)
  • [44] Prostate-specific membrane antigen radioligand therapy of prostate cancer
    Beheshti, Mohsen
    Heinzel, Alexander
    von Mallek, Dirk
    Filss, Christian
    Mottaghy, Felix M.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (01): : 29 - 36
  • [45] Advances in prostate-specific membrane antigen PET of prostate cancer
    Bouchelouche, Kirsten
    Choyke, Peter L.
    CURRENT OPINION IN ONCOLOGY, 2018, 30 (03) : 189 - 196
  • [46] Re: Prostate-Specific Membrane Antigen PET in Prostate Cancer
    Siegel, Cary
    JOURNAL OF UROLOGY, 2021, 206 (04): : 1044 - 1044
  • [48] Prostate-specific membrane antigen as a marker of pancreatic cancer cells
    He Ren
    Huan Zhang
    Xiuchao Wang
    Junxiu Liu
    Zhanna Yuan
    Jihui Hao
    Medical Oncology, 2014, 31
  • [49] Updates of prostate cancer staging: Prostate-specific membrane antigen
    Sathianathen, Niranjan J.
    Lamb, Alastair
    Nair, Rajesh
    Geurts, Nicolas
    Mitchell, Catherine
    Lawrentschuk, Nathan L.
    Moon, Daniel A.
    Murphy, Declan G.
    INVESTIGATIVE AND CLINICAL UROLOGY, 2016, 57 : S147 - S154
  • [50] Targeting the prostate-specific membrane antigen for prostate cancer therapy
    Buehler, Patrick
    Wolf, Philipp
    Elsaesser-Beile, Ursula
    IMMUNOTHERAPY, 2009, 1 (03) : 471 - 481